Cargando…
Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
(1) Background: Theranostic approaches in the management of cholecystokinin subtype 2 receptor (CCK(2)R)-positive tumors include radiolabeled gastrin and CCK motifs. Moving toward antagonist-based CCK(2)R-radioligands instead, we herein present three analogs of the nonpeptidic CCK(2)R-antagonist Z36...
Autores principales: | Nock, Berthold A., Kanellopoulos, Panagiotis, Chepurny, Oleg G., Rouchota, Maritina, Loudos, George, Holz, George G., Krenning, Eric P., Maina, Theodosia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954547/ https://www.ncbi.nlm.nih.gov/pubmed/35336041 http://dx.doi.org/10.3390/pharmaceutics14030666 |
Ejemplares similares
-
Side-Chain Modified [(99m)Tc]Tc-DT1 Mimics: A Comparative Study in NTS(1)R-Positive Models
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2023) -
One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [(99m)Tc]Tc-DB4 and [(111)In]In-SG4 in Mice Treated with Entresto
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020) -
[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023) -
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023) -
Optimizing the Profile of [(99m)Tc]Tc–NT(7–13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors
por: Kanellopoulos, Panagiotis, et al.
Publicado: (2020)